Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD presents Cancidas study results

MSD presents Cancidas study results

18th September 2007

Merck, Sharp and Dohme (MSD) has presented clinical study results of the use of Cancidas (caspofungin acetate) as a paediatric empirical therapy of suspected invasive fungal infections in patients exhibiting neutropenia and persistent fever.

The results were presented this week at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy of the American Society for Microbiology, with the study comparing the use of Cancidas with L-AmB in this patient group with a primary endpoint being the proportion of patients treated with Cancidas experiencing more than one adverse effect.

In the study, Cancidas was found to have a similar safety profile to L-AmB, with the drug also showing a similar overall response rate and fever resolution rate.

Johan Maertens, chairman of the European Organisation for Research and Treatment of Cancer Infectious Disease Group, said: “This study represents an important step forward as it provides the first look at data on the safety and efficacy on the investigational use of Cancidas as empiric therapy in paediatric patients.”

He also noted that randomised studies connected to empiric therapies can be difficult to undertake when involving younger patients.

In July 2007, MSD announced the appointment of Kenneth C Frazier to the role of executive vice-president and president of global human health at the company.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.